Amarantus Bioscience (OTCMKTS:AMBS – Get Free Report) and BrightSpring Health Services (NASDAQ:BTSG – Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, institutional ownership, dividends, valuation and risk.
Earnings and Valuation
This table compares Amarantus Bioscience and BrightSpring Health Services”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Amarantus Bioscience | N/A | N/A | N/A | N/A | N/A |
| BrightSpring Health Services | $12.91 billion | 0.96 | $190.67 million | $1.66 | 37.61 |
Risk & Volatility
Amarantus Bioscience has a beta of 1.57, meaning that its share price is 57% more volatile than the S&P 500. Comparatively, BrightSpring Health Services has a beta of 1.88, meaning that its share price is 88% more volatile than the S&P 500.
Profitability
This table compares Amarantus Bioscience and BrightSpring Health Services’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Amarantus Bioscience | N/A | N/A | N/A |
| BrightSpring Health Services | 2.55% | 16.73% | 5.24% |
Analyst Ratings
This is a breakdown of recent ratings for Amarantus Bioscience and BrightSpring Health Services, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Amarantus Bioscience | 0 | 0 | 0 | 0 | 0.00 |
| BrightSpring Health Services | 0 | 0 | 18 | 2 | 3.10 |
BrightSpring Health Services has a consensus price target of $70.71, suggesting a potential upside of 13.26%. Given BrightSpring Health Services’ stronger consensus rating and higher possible upside, analysts plainly believe BrightSpring Health Services is more favorable than Amarantus Bioscience.
Summary
BrightSpring Health Services beats Amarantus Bioscience on 9 of the 9 factors compared between the two stocks.
About Amarantus Bioscience
Amarantus BioScience Holdings, Inc., a biopharmaceutical company, focuses on the development of diagnostic and therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology, and regenerative medicine. The company's diagnostic products in development include the lymphocyte proliferation (LymPro) test, a diagnostic blood test for Alzheimer's disease; and MSPrecise, a proprietary DNA sequencing assay for the identification of patients with multiple sclerosis. Its therapeutic products in development comprise Eltoprazine, a small molecule drug for the treatment of Parkinson's disease Levadopa-Induced Dyskinesia and attention deficit hyperactivity disorders; and mesencephalic-astrocyte-derived neurotrophic factor for the treatment of various animal models, including retinitis pigmentosa and retinal artery occlusion. It also develops NuroPro, a neurodegenerative disease diagnostic platform with application in Parkinson's disease; BC-SeraPro, an oncology diagnostic platform with application in breast cancer; and PhenoGuard platform for neurrotrophic factor discovery. In addition, the company develops Engineered Skin Substitute (ESS), a cell therapy-based autologous skin replacement product that is in mid-stage clinical development for the treatment of life-threatening severe burns. Amarantus BioScience Holdings, Inc. has a cooperative research and development agreement with the U.S. Army Institute of Surgical Research and Rutgers University. The company was formerly known as Amarantus Bioscience, Inc. and changed its name to Amarantus BioScience Holdings, Inc. in April 2013. Amarantus BioScience Holdings, Inc. was founded in 2008 and is headquartered in New York, New York.
About BrightSpring Health Services
BrightSpring Health Services, Inc. operates a home and community-based healthcare services platform in the United States. The company's platform focuses on delivering pharmacy and provider services, including clinical and supportive care in home and community settings to Medicare, Medicaid, and insured populations. It serves patients through clinical providers and pharmacists. The company was formerly known as Phoenix Parent Holdings Inc. and changed its name to BrightSpring Health Services, Inc. in May 2021. BrightSpring Health Services, Inc. was founded in 1974 and is headquartered in Louisville, Kentucky.
Receive News & Ratings for Amarantus Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarantus Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
